nodes	percent_of_prediction	percent_of_DWPC	metapath
Atomoxetine—CYP2D6—Vinorelbine—ovarian cancer	0.028	0.255	CbGbCtD
Atomoxetine—CYP3A4—Topotecan—ovarian cancer	0.0253	0.23	CbGbCtD
Atomoxetine—CYP3A4—Vinorelbine—ovarian cancer	0.0178	0.162	CbGbCtD
Atomoxetine—HTR2A—vein—ovarian cancer	0.0127	0.117	CbGeAlD
Atomoxetine—CYP3A4—Paclitaxel—ovarian cancer	0.0125	0.114	CbGbCtD
Atomoxetine—NPY1R—myometrium—ovarian cancer	0.0122	0.113	CbGeAlD
Atomoxetine—CYP2D6—Doxorubicin—ovarian cancer	0.0106	0.0964	CbGbCtD
Atomoxetine—NPY1R—uterine cervix—ovarian cancer	0.00951	0.0877	CbGeAlD
Atomoxetine—CYP3A4—Docetaxel—ovarian cancer	0.00904	0.0822	CbGbCtD
Atomoxetine—NPY1R—gonad—ovarian cancer	0.00798	0.0736	CbGeAlD
Atomoxetine—NPY1R—female reproductive system—ovarian cancer	0.00712	0.0657	CbGeAlD
Atomoxetine—CYP3A4—Doxorubicin—ovarian cancer	0.00674	0.0613	CbGbCtD
Atomoxetine—NPY1R—vagina—ovarian cancer	0.00644	0.0594	CbGeAlD
Atomoxetine—NPY1R—testis—ovarian cancer	0.00575	0.053	CbGeAlD
Atomoxetine—Pseudoephedrine—IL2—ovarian cancer	0.00551	0.382	CrCbGaD
Atomoxetine—NPY1R—lymph node—ovarian cancer	0.00417	0.0385	CbGeAlD
Atomoxetine—SLC6A2—decidua—ovarian cancer	0.00307	0.0284	CbGeAlD
Atomoxetine—HTR1B—female reproductive system—ovarian cancer	0.00302	0.0279	CbGeAlD
Atomoxetine—HTR1D—female reproductive system—ovarian cancer	0.00293	0.027	CbGeAlD
Atomoxetine—HTR2C—female reproductive system—ovarian cancer	0.0029	0.0267	CbGeAlD
Atomoxetine—SLC6A4—female reproductive system—ovarian cancer	0.00275	0.0253	CbGeAlD
Atomoxetine—SLC6A2—gonad—ovarian cancer	0.00271	0.025	CbGeAlD
Atomoxetine—Ketoprofen—CXCL8—ovarian cancer	0.00246	0.17	CrCbGaD
Atomoxetine—SLC6A3—testis—ovarian cancer	0.00242	0.0223	CbGeAlD
Atomoxetine—SLC6A2—female reproductive system—ovarian cancer	0.00242	0.0223	CbGeAlD
Atomoxetine—HTR2A—embryo—ovarian cancer	0.0024	0.0221	CbGeAlD
Atomoxetine—CYP2C19—vagina—ovarian cancer	0.00206	0.019	CbGeAlD
Atomoxetine—HTR2A—epithelium—ovarian cancer	0.00196	0.0181	CbGeAlD
Atomoxetine—SLC6A2—testis—ovarian cancer	0.00195	0.018	CbGeAlD
Atomoxetine—HTR2A—gonad—ovarian cancer	0.00163	0.015	CbGeAlD
Atomoxetine—HTR2A—female reproductive system—ovarian cancer	0.00145	0.0134	CbGeAlD
Atomoxetine—SLC6A2—lymph node—ovarian cancer	0.00141	0.0131	CbGeAlD
Atomoxetine—Reboxetine—ABCB1—ovarian cancer	0.00138	0.0957	CrCbGaD
Atomoxetine—CYP3A4—female reproductive system—ovarian cancer	0.00135	0.0124	CbGeAlD
Atomoxetine—CYP2D6—female reproductive system—ovarian cancer	0.00132	0.0122	CbGeAlD
Atomoxetine—HTR2A—vagina—ovarian cancer	0.00131	0.0121	CbGeAlD
Atomoxetine—Protriptyline—ABCB1—ovarian cancer	0.00127	0.0879	CrCbGaD
Atomoxetine—CYP2D6—female gonad—ovarian cancer	0.0012	0.0111	CbGeAlD
Atomoxetine—HTR2A—testis—ovarian cancer	0.00117	0.0108	CbGeAlD
Atomoxetine—CYP2D6—testis—ovarian cancer	0.00107	0.00986	CbGeAlD
Atomoxetine—Palpitations—Paclitaxel—ovarian cancer	0.00105	0.00153	CcSEcCtD
Atomoxetine—Angiopathy—Docetaxel—ovarian cancer	0.00105	0.00153	CcSEcCtD
Atomoxetine—Vomiting—Melphalan—ovarian cancer	0.00105	0.00153	CcSEcCtD
Atomoxetine—Loss of consciousness—Paclitaxel—ovarian cancer	0.00104	0.00152	CcSEcCtD
Atomoxetine—Mediastinal disorder—Docetaxel—ovarian cancer	0.00104	0.00152	CcSEcCtD
Atomoxetine—Rash—Melphalan—ovarian cancer	0.00104	0.00152	CcSEcCtD
Atomoxetine—Dermatitis—Melphalan—ovarian cancer	0.00104	0.00152	CcSEcCtD
Atomoxetine—Chills—Docetaxel—ovarian cancer	0.00104	0.00151	CcSEcCtD
Atomoxetine—Cough—Paclitaxel—ovarian cancer	0.00103	0.00151	CcSEcCtD
Atomoxetine—Asthenia—Vinorelbine—ovarian cancer	0.00103	0.00151	CcSEcCtD
Atomoxetine—Abdominal pain upper—Epirubicin—ovarian cancer	0.00103	0.0015	CcSEcCtD
Atomoxetine—Convulsion—Paclitaxel—ovarian cancer	0.00103	0.0015	CcSEcCtD
Atomoxetine—Affect lability—Doxorubicin—ovarian cancer	0.00103	0.0015	CcSEcCtD
Atomoxetine—Pruritus—Vinorelbine—ovarian cancer	0.00102	0.00149	CcSEcCtD
Atomoxetine—Breast disorder—Epirubicin—ovarian cancer	0.00102	0.00149	CcSEcCtD
Atomoxetine—Mental disorder—Docetaxel—ovarian cancer	0.00101	0.00148	CcSEcCtD
Atomoxetine—Chest pain—Paclitaxel—ovarian cancer	0.00101	0.00147	CcSEcCtD
Atomoxetine—Myalgia—Paclitaxel—ovarian cancer	0.00101	0.00147	CcSEcCtD
Atomoxetine—Arthralgia—Paclitaxel—ovarian cancer	0.00101	0.00147	CcSEcCtD
Atomoxetine—Nasopharyngitis—Epirubicin—ovarian cancer	0.00101	0.00147	CcSEcCtD
Atomoxetine—Anxiety—Paclitaxel—ovarian cancer	0.00101	0.00147	CcSEcCtD
Atomoxetine—Malnutrition—Docetaxel—ovarian cancer	0.001	0.00147	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.001	0.00146	CcSEcCtD
Atomoxetine—Nausea—Topotecan—ovarian cancer	0.000999	0.00146	CcSEcCtD
Atomoxetine—Dry mouth—Paclitaxel—ovarian cancer	0.000987	0.00144	CcSEcCtD
Atomoxetine—Mood swings—Doxorubicin—ovarian cancer	0.000987	0.00144	CcSEcCtD
Atomoxetine—Diarrhoea—Vinorelbine—ovarian cancer	0.000984	0.00144	CcSEcCtD
Atomoxetine—Dysgeusia—Docetaxel—ovarian cancer	0.000984	0.00144	CcSEcCtD
Atomoxetine—Nausea—Melphalan—ovarian cancer	0.000978	0.00143	CcSEcCtD
Atomoxetine—Influenza—Epirubicin—ovarian cancer	0.000973	0.00142	CcSEcCtD
Atomoxetine—Back pain—Docetaxel—ovarian cancer	0.000972	0.00142	CcSEcCtD
Atomoxetine—Muscle spasms—Docetaxel—ovarian cancer	0.000966	0.00141	CcSEcCtD
Atomoxetine—Infection—Paclitaxel—ovarian cancer	0.000961	0.0014	CcSEcCtD
Atomoxetine—Shock—Paclitaxel—ovarian cancer	0.000952	0.00139	CcSEcCtD
Atomoxetine—Dizziness—Vinorelbine—ovarian cancer	0.000951	0.00139	CcSEcCtD
Atomoxetine—Abdominal pain upper—Doxorubicin—ovarian cancer	0.000951	0.00139	CcSEcCtD
Atomoxetine—Nervous system disorder—Paclitaxel—ovarian cancer	0.000949	0.00139	CcSEcCtD
Atomoxetine—Tachycardia—Paclitaxel—ovarian cancer	0.000944	0.00138	CcSEcCtD
Atomoxetine—Breast disorder—Doxorubicin—ovarian cancer	0.000941	0.00137	CcSEcCtD
Atomoxetine—Skin disorder—Paclitaxel—ovarian cancer	0.00094	0.00137	CcSEcCtD
Atomoxetine—Hyperhidrosis—Paclitaxel—ovarian cancer	0.000935	0.00137	CcSEcCtD
Atomoxetine—Nasopharyngitis—Doxorubicin—ovarian cancer	0.000931	0.00136	CcSEcCtD
Atomoxetine—Anorexia—Paclitaxel—ovarian cancer	0.000922	0.00135	CcSEcCtD
Atomoxetine—Vomiting—Vinorelbine—ovarian cancer	0.000915	0.00134	CcSEcCtD
Atomoxetine—Dysuria—Epirubicin—ovarian cancer	0.00091	0.00133	CcSEcCtD
Atomoxetine—Rash—Vinorelbine—ovarian cancer	0.000907	0.00132	CcSEcCtD
Atomoxetine—Dermatitis—Vinorelbine—ovarian cancer	0.000906	0.00132	CcSEcCtD
Atomoxetine—Upper respiratory tract infection—Epirubicin—ovarian cancer	0.000904	0.00132	CcSEcCtD
Atomoxetine—Headache—Vinorelbine—ovarian cancer	0.000901	0.00132	CcSEcCtD
Atomoxetine—Syncope—Docetaxel—ovarian cancer	0.000901	0.00132	CcSEcCtD
Atomoxetine—Influenza—Doxorubicin—ovarian cancer	0.0009	0.00131	CcSEcCtD
Atomoxetine—Pollakiuria—Epirubicin—ovarian cancer	0.000899	0.00131	CcSEcCtD
Atomoxetine—Palpitations—Docetaxel—ovarian cancer	0.000888	0.0013	CcSEcCtD
Atomoxetine—Loss of consciousness—Docetaxel—ovarian cancer	0.000883	0.00129	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000882	0.00129	CcSEcCtD
Atomoxetine—Weight decreased—Epirubicin—ovarian cancer	0.00088	0.00129	CcSEcCtD
Atomoxetine—Cough—Docetaxel—ovarian cancer	0.000877	0.00128	CcSEcCtD
Atomoxetine—Insomnia—Paclitaxel—ovarian cancer	0.000875	0.00128	CcSEcCtD
Atomoxetine—Convulsion—Docetaxel—ovarian cancer	0.000871	0.00127	CcSEcCtD
Atomoxetine—Paraesthesia—Paclitaxel—ovarian cancer	0.000869	0.00127	CcSEcCtD
Atomoxetine—Infestation NOS—Epirubicin—ovarian cancer	0.000867	0.00127	CcSEcCtD
Atomoxetine—Infestation—Epirubicin—ovarian cancer	0.000867	0.00127	CcSEcCtD
Atomoxetine—Fluoxetine—ABCB1—ovarian cancer	0.000866	0.06	CrCbGaD
Atomoxetine—Somnolence—Paclitaxel—ovarian cancer	0.00086	0.00126	CcSEcCtD
Atomoxetine—Myalgia—Docetaxel—ovarian cancer	0.000856	0.00125	CcSEcCtD
Atomoxetine—Chest pain—Docetaxel—ovarian cancer	0.000856	0.00125	CcSEcCtD
Atomoxetine—Arthralgia—Docetaxel—ovarian cancer	0.000856	0.00125	CcSEcCtD
Atomoxetine—Nausea—Vinorelbine—ovarian cancer	0.000855	0.00125	CcSEcCtD
Atomoxetine—Dyspepsia—Paclitaxel—ovarian cancer	0.000852	0.00124	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.00085	0.00124	CcSEcCtD
Atomoxetine—Conjunctivitis—Epirubicin—ovarian cancer	0.000843	0.00123	CcSEcCtD
Atomoxetine—Dysuria—Doxorubicin—ovarian cancer	0.000842	0.00123	CcSEcCtD
Atomoxetine—Decreased appetite—Paclitaxel—ovarian cancer	0.000841	0.00123	CcSEcCtD
Atomoxetine—Dry mouth—Docetaxel—ovarian cancer	0.000837	0.00122	CcSEcCtD
Atomoxetine—Upper respiratory tract infection—Doxorubicin—ovarian cancer	0.000837	0.00122	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000835	0.00122	CcSEcCtD
Atomoxetine—Fatigue—Paclitaxel—ovarian cancer	0.000834	0.00122	CcSEcCtD
Atomoxetine—Pollakiuria—Doxorubicin—ovarian cancer	0.000832	0.00121	CcSEcCtD
Atomoxetine—Constipation—Paclitaxel—ovarian cancer	0.000827	0.00121	CcSEcCtD
Atomoxetine—Pain—Paclitaxel—ovarian cancer	0.000827	0.00121	CcSEcCtD
Atomoxetine—Infection—Docetaxel—ovarian cancer	0.000815	0.00119	CcSEcCtD
Atomoxetine—Weight decreased—Doxorubicin—ovarian cancer	0.000814	0.00119	CcSEcCtD
Atomoxetine—Sinusitis—Epirubicin—ovarian cancer	0.000814	0.00119	CcSEcCtD
Atomoxetine—Maprotiline—ABCB1—ovarian cancer	0.000809	0.0561	CrCbGaD
Atomoxetine—Shock—Docetaxel—ovarian cancer	0.000807	0.00118	CcSEcCtD
Atomoxetine—Nervous system disorder—Docetaxel—ovarian cancer	0.000804	0.00117	CcSEcCtD
Atomoxetine—Infestation NOS—Doxorubicin—ovarian cancer	0.000803	0.00117	CcSEcCtD
Atomoxetine—Infestation—Doxorubicin—ovarian cancer	0.000803	0.00117	CcSEcCtD
Atomoxetine—Tachycardia—Docetaxel—ovarian cancer	0.0008	0.00117	CcSEcCtD
Atomoxetine—Feeling abnormal—Paclitaxel—ovarian cancer	0.000797	0.00116	CcSEcCtD
Atomoxetine—Skin disorder—Docetaxel—ovarian cancer	0.000797	0.00116	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000791	0.00116	CcSEcCtD
Atomoxetine—Anorexia—Docetaxel—ovarian cancer	0.000782	0.00114	CcSEcCtD
Atomoxetine—Conjunctivitis—Doxorubicin—ovarian cancer	0.00078	0.00114	CcSEcCtD
Atomoxetine—Hypoaesthesia—Epirubicin—ovarian cancer	0.000775	0.00113	CcSEcCtD
Atomoxetine—Propafenone—ABCB1—ovarian cancer	0.000771	0.0535	CrCbGaD
Atomoxetine—Urinary tract disorder—Epirubicin—ovarian cancer	0.000769	0.00112	CcSEcCtD
Atomoxetine—Urticaria—Paclitaxel—ovarian cancer	0.000769	0.00112	CcSEcCtD
Atomoxetine—Abdominal pain—Paclitaxel—ovarian cancer	0.000765	0.00112	CcSEcCtD
Atomoxetine—Body temperature increased—Paclitaxel—ovarian cancer	0.000765	0.00112	CcSEcCtD
Atomoxetine—Urethral disorder—Epirubicin—ovarian cancer	0.000763	0.00111	CcSEcCtD
Atomoxetine—Sinusitis—Doxorubicin—ovarian cancer	0.000753	0.0011	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000747	0.00109	CcSEcCtD
Atomoxetine—Insomnia—Docetaxel—ovarian cancer	0.000742	0.00108	CcSEcCtD
Atomoxetine—Paraesthesia—Docetaxel—ovarian cancer	0.000736	0.00108	CcSEcCtD
Atomoxetine—Somnolence—Docetaxel—ovarian cancer	0.000729	0.00107	CcSEcCtD
Atomoxetine—Cardiac disorder—Epirubicin—ovarian cancer	0.000723	0.00106	CcSEcCtD
Atomoxetine—Flushing—Epirubicin—ovarian cancer	0.000723	0.00106	CcSEcCtD
Atomoxetine—Dyspepsia—Docetaxel—ovarian cancer	0.000722	0.00105	CcSEcCtD
Atomoxetine—Hypoaesthesia—Doxorubicin—ovarian cancer	0.000717	0.00105	CcSEcCtD
Atomoxetine—Decreased appetite—Docetaxel—ovarian cancer	0.000713	0.00104	CcSEcCtD
Atomoxetine—Urinary tract disorder—Doxorubicin—ovarian cancer	0.000712	0.00104	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000708	0.00103	CcSEcCtD
Atomoxetine—Fatigue—Docetaxel—ovarian cancer	0.000707	0.00103	CcSEcCtD
Atomoxetine—Angiopathy—Epirubicin—ovarian cancer	0.000706	0.00103	CcSEcCtD
Atomoxetine—Urethral disorder—Doxorubicin—ovarian cancer	0.000706	0.00103	CcSEcCtD
Atomoxetine—Mediastinal disorder—Epirubicin—ovarian cancer	0.000702	0.00103	CcSEcCtD
Atomoxetine—Constipation—Docetaxel—ovarian cancer	0.000701	0.00102	CcSEcCtD
Atomoxetine—Pain—Docetaxel—ovarian cancer	0.000701	0.00102	CcSEcCtD
Atomoxetine—Chills—Epirubicin—ovarian cancer	0.000699	0.00102	CcSEcCtD
Atomoxetine—Asthenia—Paclitaxel—ovarian cancer	0.000694	0.00101	CcSEcCtD
Atomoxetine—Pruritus—Paclitaxel—ovarian cancer	0.000685	0.001	CcSEcCtD
Atomoxetine—Mental disorder—Epirubicin—ovarian cancer	0.000682	0.000996	CcSEcCtD
Atomoxetine—Malnutrition—Epirubicin—ovarian cancer	0.000678	0.00099	CcSEcCtD
Atomoxetine—Feeling abnormal—Docetaxel—ovarian cancer	0.000676	0.000987	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000671	0.00098	CcSEcCtD
Atomoxetine—Flushing—Doxorubicin—ovarian cancer	0.000669	0.000977	CcSEcCtD
Atomoxetine—Cardiac disorder—Doxorubicin—ovarian cancer	0.000669	0.000977	CcSEcCtD
Atomoxetine—Flatulence—Epirubicin—ovarian cancer	0.000668	0.000976	CcSEcCtD
Atomoxetine—Tension—Epirubicin—ovarian cancer	0.000665	0.000972	CcSEcCtD
Atomoxetine—Dysgeusia—Epirubicin—ovarian cancer	0.000664	0.00097	CcSEcCtD
Atomoxetine—Diarrhoea—Paclitaxel—ovarian cancer	0.000662	0.000967	CcSEcCtD
Atomoxetine—Nervousness—Epirubicin—ovarian cancer	0.000658	0.000962	CcSEcCtD
Atomoxetine—Back pain—Epirubicin—ovarian cancer	0.000656	0.000958	CcSEcCtD
Atomoxetine—Angiopathy—Doxorubicin—ovarian cancer	0.000654	0.000955	CcSEcCtD
Atomoxetine—Muscle spasms—Epirubicin—ovarian cancer	0.000652	0.000952	CcSEcCtD
Atomoxetine—Mediastinal disorder—Doxorubicin—ovarian cancer	0.000649	0.000948	CcSEcCtD
Atomoxetine—Abdominal pain—Docetaxel—ovarian cancer	0.000648	0.000947	CcSEcCtD
Atomoxetine—Body temperature increased—Docetaxel—ovarian cancer	0.000648	0.000947	CcSEcCtD
Atomoxetine—Chills—Doxorubicin—ovarian cancer	0.000646	0.000944	CcSEcCtD
Atomoxetine—Dizziness—Paclitaxel—ovarian cancer	0.00064	0.000935	CcSEcCtD
Atomoxetine—Vision blurred—Epirubicin—ovarian cancer	0.000639	0.000933	CcSEcCtD
Atomoxetine—Mental disorder—Doxorubicin—ovarian cancer	0.000631	0.000922	CcSEcCtD
Atomoxetine—Malnutrition—Doxorubicin—ovarian cancer	0.000627	0.000916	CcSEcCtD
Atomoxetine—Agitation—Epirubicin—ovarian cancer	0.000623	0.00091	CcSEcCtD
Atomoxetine—Flatulence—Doxorubicin—ovarian cancer	0.000618	0.000903	CcSEcCtD
Atomoxetine—Tension—Doxorubicin—ovarian cancer	0.000615	0.000899	CcSEcCtD
Atomoxetine—Vomiting—Paclitaxel—ovarian cancer	0.000615	0.000899	CcSEcCtD
Atomoxetine—Dysgeusia—Doxorubicin—ovarian cancer	0.000614	0.000897	CcSEcCtD
Atomoxetine—Rash—Paclitaxel—ovarian cancer	0.00061	0.000891	CcSEcCtD
Atomoxetine—Dermatitis—Paclitaxel—ovarian cancer	0.00061	0.00089	CcSEcCtD
Atomoxetine—Nervousness—Doxorubicin—ovarian cancer	0.000609	0.00089	CcSEcCtD
Atomoxetine—Vertigo—Epirubicin—ovarian cancer	0.000609	0.00089	CcSEcCtD
Atomoxetine—Syncope—Epirubicin—ovarian cancer	0.000608	0.000888	CcSEcCtD
Atomoxetine—Back pain—Doxorubicin—ovarian cancer	0.000607	0.000886	CcSEcCtD
Atomoxetine—Headache—Paclitaxel—ovarian cancer	0.000606	0.000885	CcSEcCtD
Atomoxetine—Muscle spasms—Doxorubicin—ovarian cancer	0.000603	0.000881	CcSEcCtD
Atomoxetine—Palpitations—Epirubicin—ovarian cancer	0.000599	0.000875	CcSEcCtD
Atomoxetine—Loss of consciousness—Epirubicin—ovarian cancer	0.000596	0.00087	CcSEcCtD
Atomoxetine—Cough—Epirubicin—ovarian cancer	0.000591	0.000864	CcSEcCtD
Atomoxetine—Vision blurred—Doxorubicin—ovarian cancer	0.000591	0.000863	CcSEcCtD
Atomoxetine—Asthenia—Docetaxel—ovarian cancer	0.000588	0.00086	CcSEcCtD
Atomoxetine—Convulsion—Epirubicin—ovarian cancer	0.000587	0.000858	CcSEcCtD
Atomoxetine—Pruritus—Docetaxel—ovarian cancer	0.00058	0.000848	CcSEcCtD
Atomoxetine—Chest pain—Epirubicin—ovarian cancer	0.000577	0.000843	CcSEcCtD
Atomoxetine—Myalgia—Epirubicin—ovarian cancer	0.000577	0.000843	CcSEcCtD
Atomoxetine—Arthralgia—Epirubicin—ovarian cancer	0.000577	0.000843	CcSEcCtD
Atomoxetine—Agitation—Doxorubicin—ovarian cancer	0.000576	0.000842	CcSEcCtD
Atomoxetine—Anxiety—Epirubicin—ovarian cancer	0.000575	0.00084	CcSEcCtD
Atomoxetine—Nausea—Paclitaxel—ovarian cancer	0.000575	0.00084	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000573	0.000837	CcSEcCtD
Atomoxetine—Dry mouth—Epirubicin—ovarian cancer	0.000564	0.000824	CcSEcCtD
Atomoxetine—Vertigo—Doxorubicin—ovarian cancer	0.000563	0.000823	CcSEcCtD
Atomoxetine—Syncope—Doxorubicin—ovarian cancer	0.000562	0.000822	CcSEcCtD
Atomoxetine—Diarrhoea—Docetaxel—ovarian cancer	0.000561	0.00082	CcSEcCtD
Atomoxetine—Palpitations—Doxorubicin—ovarian cancer	0.000554	0.00081	CcSEcCtD
Atomoxetine—Loss of consciousness—Doxorubicin—ovarian cancer	0.000551	0.000805	CcSEcCtD
Atomoxetine—Infection—Epirubicin—ovarian cancer	0.00055	0.000803	CcSEcCtD
Atomoxetine—Cough—Doxorubicin—ovarian cancer	0.000547	0.000799	CcSEcCtD
Atomoxetine—Shock—Epirubicin—ovarian cancer	0.000544	0.000795	CcSEcCtD
Atomoxetine—Convulsion—Doxorubicin—ovarian cancer	0.000543	0.000794	CcSEcCtD
Atomoxetine—Nervous system disorder—Epirubicin—ovarian cancer	0.000543	0.000792	CcSEcCtD
Atomoxetine—Dizziness—Docetaxel—ovarian cancer	0.000542	0.000792	CcSEcCtD
Atomoxetine—Tachycardia—Epirubicin—ovarian cancer	0.00054	0.000789	CcSEcCtD
Atomoxetine—Skin disorder—Epirubicin—ovarian cancer	0.000537	0.000785	CcSEcCtD
Atomoxetine—Hyperhidrosis—Epirubicin—ovarian cancer	0.000535	0.000781	CcSEcCtD
Atomoxetine—Myalgia—Doxorubicin—ovarian cancer	0.000534	0.00078	CcSEcCtD
Atomoxetine—Chest pain—Doxorubicin—ovarian cancer	0.000534	0.00078	CcSEcCtD
Atomoxetine—Arthralgia—Doxorubicin—ovarian cancer	0.000534	0.00078	CcSEcCtD
Atomoxetine—Anxiety—Doxorubicin—ovarian cancer	0.000532	0.000777	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.00053	0.000775	CcSEcCtD
Atomoxetine—Propranolol—ABCB1—ovarian cancer	0.000528	0.0366	CrCbGaD
Atomoxetine—Anorexia—Epirubicin—ovarian cancer	0.000527	0.00077	CcSEcCtD
Atomoxetine—Dry mouth—Doxorubicin—ovarian cancer	0.000522	0.000763	CcSEcCtD
Atomoxetine—Vomiting—Docetaxel—ovarian cancer	0.000521	0.000762	CcSEcCtD
Atomoxetine—Rash—Docetaxel—ovarian cancer	0.000517	0.000755	CcSEcCtD
Atomoxetine—Dermatitis—Docetaxel—ovarian cancer	0.000517	0.000755	CcSEcCtD
Atomoxetine—Headache—Docetaxel—ovarian cancer	0.000514	0.000751	CcSEcCtD
Atomoxetine—Infection—Doxorubicin—ovarian cancer	0.000509	0.000743	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000504	0.000736	CcSEcCtD
Atomoxetine—Shock—Doxorubicin—ovarian cancer	0.000504	0.000736	CcSEcCtD
Atomoxetine—Nervous system disorder—Doxorubicin—ovarian cancer	0.000502	0.000733	CcSEcCtD
Atomoxetine—Insomnia—Epirubicin—ovarian cancer	0.0005	0.000731	CcSEcCtD
Atomoxetine—Tachycardia—Doxorubicin—ovarian cancer	0.0005	0.00073	CcSEcCtD
Atomoxetine—Skin disorder—Doxorubicin—ovarian cancer	0.000497	0.000726	CcSEcCtD
Atomoxetine—Paraesthesia—Epirubicin—ovarian cancer	0.000497	0.000726	CcSEcCtD
Atomoxetine—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000495	0.000723	CcSEcCtD
Atomoxetine—Somnolence—Epirubicin—ovarian cancer	0.000492	0.000718	CcSEcCtD
Atomoxetine—Anorexia—Doxorubicin—ovarian cancer	0.000488	0.000713	CcSEcCtD
Atomoxetine—Nausea—Docetaxel—ovarian cancer	0.000487	0.000712	CcSEcCtD
Atomoxetine—Dyspepsia—Epirubicin—ovarian cancer	0.000487	0.000711	CcSEcCtD
Atomoxetine—Decreased appetite—Epirubicin—ovarian cancer	0.000481	0.000702	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000478	0.000698	CcSEcCtD
Atomoxetine—Fatigue—Epirubicin—ovarian cancer	0.000477	0.000697	CcSEcCtD
Atomoxetine—Pain—Epirubicin—ovarian cancer	0.000473	0.000691	CcSEcCtD
Atomoxetine—Constipation—Epirubicin—ovarian cancer	0.000473	0.000691	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000466	0.000681	CcSEcCtD
Atomoxetine—Insomnia—Doxorubicin—ovarian cancer	0.000463	0.000676	CcSEcCtD
Atomoxetine—Paraesthesia—Doxorubicin—ovarian cancer	0.00046	0.000671	CcSEcCtD
Atomoxetine—Feeling abnormal—Epirubicin—ovarian cancer	0.000456	0.000666	CcSEcCtD
Atomoxetine—Somnolence—Doxorubicin—ovarian cancer	0.000455	0.000665	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000452	0.000661	CcSEcCtD
Atomoxetine—Dyspepsia—Doxorubicin—ovarian cancer	0.000451	0.000658	CcSEcCtD
Atomoxetine—Decreased appetite—Doxorubicin—ovarian cancer	0.000445	0.00065	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000442	0.000646	CcSEcCtD
Atomoxetine—Fatigue—Doxorubicin—ovarian cancer	0.000441	0.000645	CcSEcCtD
Atomoxetine—Urticaria—Epirubicin—ovarian cancer	0.000439	0.000642	CcSEcCtD
Atomoxetine—Pain—Doxorubicin—ovarian cancer	0.000438	0.000639	CcSEcCtD
Atomoxetine—Constipation—Doxorubicin—ovarian cancer	0.000438	0.000639	CcSEcCtD
Atomoxetine—Abdominal pain—Epirubicin—ovarian cancer	0.000437	0.000639	CcSEcCtD
Atomoxetine—Body temperature increased—Epirubicin—ovarian cancer	0.000437	0.000639	CcSEcCtD
Atomoxetine—Methadone—ABCB1—ovarian cancer	0.000434	0.0301	CrCbGaD
Atomoxetine—Feeling abnormal—Doxorubicin—ovarian cancer	0.000422	0.000616	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000419	0.000611	CcSEcCtD
Atomoxetine—Urticaria—Doxorubicin—ovarian cancer	0.000407	0.000594	CcSEcCtD
Atomoxetine—Body temperature increased—Doxorubicin—ovarian cancer	0.000405	0.000591	CcSEcCtD
Atomoxetine—Abdominal pain—Doxorubicin—ovarian cancer	0.000405	0.000591	CcSEcCtD
Atomoxetine—Desipramine—ABCB1—ovarian cancer	0.0004	0.0277	CrCbGaD
Atomoxetine—Asthenia—Epirubicin—ovarian cancer	0.000397	0.00058	CcSEcCtD
Atomoxetine—Pruritus—Epirubicin—ovarian cancer	0.000391	0.000572	CcSEcCtD
Atomoxetine—Diarrhoea—Epirubicin—ovarian cancer	0.000379	0.000553	CcSEcCtD
Atomoxetine—Asthenia—Doxorubicin—ovarian cancer	0.000367	0.000536	CcSEcCtD
Atomoxetine—Dizziness—Epirubicin—ovarian cancer	0.000366	0.000534	CcSEcCtD
Atomoxetine—Pruritus—Doxorubicin—ovarian cancer	0.000362	0.000529	CcSEcCtD
Atomoxetine—Vomiting—Epirubicin—ovarian cancer	0.000352	0.000514	CcSEcCtD
Atomoxetine—Diarrhoea—Doxorubicin—ovarian cancer	0.00035	0.000512	CcSEcCtD
Atomoxetine—Rash—Epirubicin—ovarian cancer	0.000349	0.000509	CcSEcCtD
Atomoxetine—Dermatitis—Epirubicin—ovarian cancer	0.000348	0.000509	CcSEcCtD
Atomoxetine—Headache—Epirubicin—ovarian cancer	0.000347	0.000506	CcSEcCtD
Atomoxetine—Dizziness—Doxorubicin—ovarian cancer	0.000338	0.000494	CcSEcCtD
Atomoxetine—Nausea—Epirubicin—ovarian cancer	0.000329	0.00048	CcSEcCtD
Atomoxetine—Vomiting—Doxorubicin—ovarian cancer	0.000325	0.000475	CcSEcCtD
Atomoxetine—Rash—Doxorubicin—ovarian cancer	0.000323	0.000471	CcSEcCtD
Atomoxetine—Dermatitis—Doxorubicin—ovarian cancer	0.000322	0.000471	CcSEcCtD
Atomoxetine—Headache—Doxorubicin—ovarian cancer	0.000321	0.000468	CcSEcCtD
Atomoxetine—Nausea—Doxorubicin—ovarian cancer	0.000304	0.000444	CcSEcCtD
Atomoxetine—HTR1B—Signaling Pathways—APC—ovarian cancer	2.63e-05	0.000319	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PIK3CG—ovarian cancer	2.63e-05	0.000319	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—NRAS—ovarian cancer	2.63e-05	0.000319	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—IL2—ovarian cancer	2.62e-05	0.000317	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—MAPK3—ovarian cancer	2.59e-05	0.000314	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PPP2R1A—ovarian cancer	2.59e-05	0.000313	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—PIK3CB—ovarian cancer	2.59e-05	0.000313	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—PIK3CD—ovarian cancer	2.58e-05	0.000312	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—MAPK3—ovarian cancer	2.57e-05	0.000312	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—MAPK3—ovarian cancer	2.52e-05	0.000305	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—CXCL8—ovarian cancer	2.49e-05	0.000301	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—PIK3CB—ovarian cancer	2.47e-05	0.000299	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—FASN—ovarian cancer	2.47e-05	0.000299	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—MAPK1—ovarian cancer	2.47e-05	0.000299	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—EGFR—ovarian cancer	2.47e-05	0.000299	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—MAPK1—ovarian cancer	2.45e-05	0.000296	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—EGFR—ovarian cancer	2.45e-05	0.000296	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—SLC5A5—ovarian cancer	2.43e-05	0.000294	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—MAPK1—ovarian cancer	2.4e-05	0.00029	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—EGFR—ovarian cancer	2.4e-05	0.00029	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—PIK3CD—ovarian cancer	2.38e-05	0.000288	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—CXCL8—ovarian cancer	2.38e-05	0.000288	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—IL2—ovarian cancer	2.37e-05	0.000288	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TERT—ovarian cancer	2.37e-05	0.000287	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PIK3CD—ovarian cancer	2.36e-05	0.000286	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—PIK3CA—ovarian cancer	2.36e-05	0.000285	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—SLC2A1—ovarian cancer	2.34e-05	0.000284	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—PIK3CA—ovarian cancer	2.34e-05	0.000283	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—KRAS—ovarian cancer	2.33e-05	0.000282	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PIK3CD—ovarian cancer	2.31e-05	0.00028	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—KRAS—ovarian cancer	2.31e-05	0.00028	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	2.3e-05	0.000278	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—PIK3CA—ovarian cancer	2.29e-05	0.000277	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—IL2—ovarian cancer	2.27e-05	0.000275	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—FASN—ovarian cancer	2.27e-05	0.000275	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—KRAS—ovarian cancer	2.26e-05	0.000274	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CYP1B1—ovarian cancer	2.25e-05	0.000272	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—PIK3CB—ovarian cancer	2.25e-05	0.000272	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—SLC5A5—ovarian cancer	2.23e-05	0.00027	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CAV1—ovarian cancer	2.19e-05	0.000265	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—CXCL8—ovarian cancer	2.16e-05	0.000261	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—SLC2A1—ovarian cancer	2.16e-05	0.000261	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—PIK3CA—ovarian cancer	2.14e-05	0.000259	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—PIK3CA—ovarian cancer	2.12e-05	0.000257	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—ESR1—ovarian cancer	2.11e-05	0.000255	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—ERBB2—ovarian cancer	2.1e-05	0.000255	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—ERBB2—ovarian cancer	2.09e-05	0.000253	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—PIK3CA—ovarian cancer	2.08e-05	0.000252	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IL6ST—ovarian cancer	2.07e-05	0.000251	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—MTOR—ovarian cancer	2.07e-05	0.000251	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—PIK3CB—ovarian cancer	2.07e-05	0.000251	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CYP1B1—ovarian cancer	2.07e-05	0.00025	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—IL2—ovarian cancer	2.06e-05	0.00025	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—MTOR—ovarian cancer	2.06e-05	0.000249	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PIK3CB—ovarian cancer	2.06e-05	0.000249	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TERT—ovarian cancer	2.05e-05	0.000249	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—ERBB2—ovarian cancer	2.04e-05	0.000247	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PIK3CB—ovarian cancer	2.02e-05	0.000244	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MTOR—ovarian cancer	2.02e-05	0.000244	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PPP2R1A—ovarian cancer	1.99e-05	0.000241	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—APC—ovarian cancer	1.99e-05	0.000241	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PIK3CG—ovarian cancer	1.99e-05	0.000241	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—NRAS—ovarian cancer	1.99e-05	0.000241	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CXCL8—ovarian cancer	1.99e-05	0.000241	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.98e-05	0.00024	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—HRAS—ovarian cancer	1.98e-05	0.00024	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CXCL8—ovarian cancer	1.98e-05	0.00024	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—HRAS—ovarian cancer	1.97e-05	0.000238	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CDKN1B—ovarian cancer	1.95e-05	0.000236	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CXCL8—ovarian cancer	1.94e-05	0.000235	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CDKN1B—ovarian cancer	1.93e-05	0.000234	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—AKT1—ovarian cancer	1.93e-05	0.000233	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—HRAS—ovarian cancer	1.92e-05	0.000233	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—AKT1—ovarian cancer	1.91e-05	0.000231	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—MAPK3—ovarian cancer	1.91e-05	0.000231	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CASP3—ovarian cancer	1.91e-05	0.000231	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—IL2—ovarian cancer	1.91e-05	0.000231	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CAV1—ovarian cancer	1.9e-05	0.00023	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—IL6—ovarian cancer	1.9e-05	0.00023	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CASP3—ovarian cancer	1.89e-05	0.000229	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CDKN1B—ovarian cancer	1.89e-05	0.000229	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—IL2—ovarian cancer	1.89e-05	0.000229	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—IL6—ovarian cancer	1.88e-05	0.000228	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—AKT1—ovarian cancer	1.87e-05	0.000227	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CCND1—ovarian cancer	1.86e-05	0.000225	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CASP3—ovarian cancer	1.85e-05	0.000224	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—ABCB1—ovarian cancer	1.85e-05	0.000224	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—IL2—ovarian cancer	1.85e-05	0.000224	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CCND1—ovarian cancer	1.84e-05	0.000223	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—IL6—ovarian cancer	1.84e-05	0.000223	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CTNNB1—ovarian cancer	1.84e-05	0.000223	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PPP2R1A—ovarian cancer	1.83e-05	0.000222	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—ESR1—ovarian cancer	1.83e-05	0.000222	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CTNNB1—ovarian cancer	1.83e-05	0.000221	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—YAP1—ovarian cancer	1.82e-05	0.00022	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—TYMS—ovarian cancer	1.82e-05	0.00022	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—MAPK1—ovarian cancer	1.82e-05	0.00022	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—EGFR—ovarian cancer	1.82e-05	0.00022	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CCND1—ovarian cancer	1.8e-05	0.000219	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—MMP9—ovarian cancer	1.8e-05	0.000218	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IL6ST—ovarian cancer	1.8e-05	0.000218	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—PTEN—ovarian cancer	1.79e-05	0.000217	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—MMP9—ovarian cancer	1.79e-05	0.000217	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CTNNB1—ovarian cancer	1.79e-05	0.000216	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PTEN—ovarian cancer	1.78e-05	0.000215	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PIK3CD—ovarian cancer	1.75e-05	0.000212	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MMP9—ovarian cancer	1.75e-05	0.000212	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—AKT1—ovarian cancer	1.75e-05	0.000212	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PTEN—ovarian cancer	1.74e-05	0.000211	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—PIK3CA—ovarian cancer	1.74e-05	0.00021	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—AKT1—ovarian cancer	1.74e-05	0.00021	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PIK3CG—ovarian cancer	1.73e-05	0.00021	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—APC—ovarian cancer	1.73e-05	0.00021	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—NRAS—ovarian cancer	1.73e-05	0.00021	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—KRAS—ovarian cancer	1.72e-05	0.000208	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—ABCB1—ovarian cancer	1.7e-05	0.000206	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—AKT1—ovarian cancer	1.7e-05	0.000206	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—TYMS—ovarian cancer	1.67e-05	0.000202	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—MAPK3—ovarian cancer	1.66e-05	0.000201	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—VEGFA—ovarian cancer	1.62e-05	0.000196	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—VEGFA—ovarian cancer	1.61e-05	0.000195	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—STAT3—ovarian cancer	1.6e-05	0.000194	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—NRAS—ovarian cancer	1.6e-05	0.000194	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—STAT3—ovarian cancer	1.59e-05	0.000193	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—NRAS—ovarian cancer	1.59e-05	0.000192	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—MAPK1—ovarian cancer	1.58e-05	0.000191	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—EGFR—ovarian cancer	1.58e-05	0.000191	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—PIK3CA—ovarian cancer	1.58e-05	0.000191	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—VEGFA—ovarian cancer	1.57e-05	0.000191	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—STAT3—ovarian cancer	1.56e-05	0.000189	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—NRAS—ovarian cancer	1.55e-05	0.000188	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—ERBB2—ovarian cancer	1.55e-05	0.000187	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—MAPK3—ovarian cancer	1.53e-05	0.000185	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PIK3CB—ovarian cancer	1.53e-05	0.000185	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MTOR—ovarian cancer	1.53e-05	0.000185	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PIK3CD—ovarian cancer	1.52e-05	0.000184	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—MAPK3—ovarian cancer	1.52e-05	0.000184	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—PIK3CA—ovarian cancer	1.51e-05	0.000183	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—KRAS—ovarian cancer	1.49e-05	0.00018	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—MYC—ovarian cancer	1.49e-05	0.00018	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MAPK3—ovarian cancer	1.49e-05	0.00018	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—FASN—ovarian cancer	1.48e-05	0.00018	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—MYC—ovarian cancer	1.48e-05	0.000179	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CXCL8—ovarian cancer	1.47e-05	0.000178	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CAV1—ovarian cancer	1.47e-05	0.000177	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—SLC5A5—ovarian cancer	1.46e-05	0.000177	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—HRAS—ovarian cancer	1.46e-05	0.000177	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—MAPK1—ovarian cancer	1.46e-05	0.000176	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—EGFR—ovarian cancer	1.46e-05	0.000176	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MYC—ovarian cancer	1.45e-05	0.000175	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—MAPK1—ovarian cancer	1.45e-05	0.000175	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—EGFR—ovarian cancer	1.45e-05	0.000175	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CDKN1B—ovarian cancer	1.43e-05	0.000174	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—AKT1—ovarian cancer	1.42e-05	0.000172	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MAPK1—ovarian cancer	1.42e-05	0.000171	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—EGFR—ovarian cancer	1.42e-05	0.000171	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—SLC2A1—ovarian cancer	1.41e-05	0.000171	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CASP3—ovarian cancer	1.41e-05	0.00017	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IL2—ovarian cancer	1.4e-05	0.00017	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.4e-05	0.000169	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—IL6—ovarian cancer	1.4e-05	0.000169	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—KRAS—ovarian cancer	1.38e-05	0.000167	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—PIK3CA—ovarian cancer	1.37e-05	0.000166	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CCND1—ovarian cancer	1.37e-05	0.000166	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—KRAS—ovarian cancer	1.37e-05	0.000165	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CTNNB1—ovarian cancer	1.35e-05	0.000164	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CYP1B1—ovarian cancer	1.35e-05	0.000164	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CAV1—ovarian cancer	1.35e-05	0.000163	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—ERBB2—ovarian cancer	1.34e-05	0.000163	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—KRAS—ovarian cancer	1.34e-05	0.000162	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PIK3CG—ovarian cancer	1.33e-05	0.000162	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MMP9—ovarian cancer	1.33e-05	0.000161	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MTOR—ovarian cancer	1.33e-05	0.000161	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PIK3CB—ovarian cancer	1.33e-05	0.000161	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PTEN—ovarian cancer	1.32e-05	0.00016	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—AKT1—ovarian cancer	1.29e-05	0.000156	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CXCL8—ovarian cancer	1.27e-05	0.000154	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—HRAS—ovarian cancer	1.27e-05	0.000153	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—PIK3CA—ovarian cancer	1.26e-05	0.000153	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PIK3CA—ovarian cancer	1.25e-05	0.000152	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CDKN1B—ovarian cancer	1.24e-05	0.000151	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—AKT1—ovarian cancer	1.23e-05	0.000149	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PIK3CA—ovarian cancer	1.23e-05	0.000149	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PIK3CG—ovarian cancer	1.23e-05	0.000149	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TP53—ovarian cancer	1.22e-05	0.000148	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CASP3—ovarian cancer	1.22e-05	0.000148	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IL2—ovarian cancer	1.22e-05	0.000148	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TP53—ovarian cancer	1.21e-05	0.000147	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—IL6—ovarian cancer	1.21e-05	0.000147	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	1.2e-05	0.000145	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—VEGFA—ovarian cancer	1.19e-05	0.000144	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TP53—ovarian cancer	1.19e-05	0.000144	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CCND1—ovarian cancer	1.19e-05	0.000144	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—STAT3—ovarian cancer	1.18e-05	0.000143	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—NRAS—ovarian cancer	1.18e-05	0.000143	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CTNNB1—ovarian cancer	1.18e-05	0.000142	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PIK3CD—ovarian cancer	1.17e-05	0.000142	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—HRAS—ovarian cancer	1.17e-05	0.000142	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—HRAS—ovarian cancer	1.16e-05	0.000141	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MMP9—ovarian cancer	1.15e-05	0.00014	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PTEN—ovarian cancer	1.15e-05	0.000139	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—HRAS—ovarian cancer	1.14e-05	0.000138	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MAPK3—ovarian cancer	1.13e-05	0.000137	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—IL6—ovarian cancer	1.12e-05	0.000136	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—AKT1—ovarian cancer	1.12e-05	0.000135	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ABCB1—ovarian cancer	1.11e-05	0.000135	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—IL6—ovarian cancer	1.11e-05	0.000135	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MYC—ovarian cancer	1.1e-05	0.000133	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—TYMS—ovarian cancer	1.09e-05	0.000132	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—IL6—ovarian cancer	1.09e-05	0.000132	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PIK3CD—ovarian cancer	1.08e-05	0.000131	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MAPK1—ovarian cancer	1.07e-05	0.00013	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—EGFR—ovarian cancer	1.07e-05	0.00013	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—VEGFA—ovarian cancer	1.04e-05	0.000125	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—AKT1—ovarian cancer	1.03e-05	0.000125	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—STAT3—ovarian cancer	1.03e-05	0.000124	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—AKT1—ovarian cancer	1.03e-05	0.000124	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—NRAS—ovarian cancer	1.02e-05	0.000124	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PIK3CB—ovarian cancer	1.02e-05	0.000124	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—KRAS—ovarian cancer	1.01e-05	0.000123	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—AKT1—ovarian cancer	1e-05	0.000122	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MAPK3—ovarian cancer	9.79e-06	0.000119	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MYC—ovarian cancer	9.53e-06	0.000115	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PIK3CB—ovarian cancer	9.41e-06	0.000114	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MAPK1—ovarian cancer	9.32e-06	0.000113	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—EGFR—ovarian cancer	9.32e-06	0.000113	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PIK3CA—ovarian cancer	9.31e-06	0.000113	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TP53—ovarian cancer	9.01e-06	0.000109	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PTEN—ovarian cancer	8.84e-06	0.000107	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CAV1—ovarian cancer	8.81e-06	0.000107	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—KRAS—ovarian cancer	8.8e-06	0.000107	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—HRAS—ovarian cancer	8.62e-06	0.000104	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IL6—ovarian cancer	8.25e-06	9.99e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PTEN—ovarian cancer	8.13e-06	9.84e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PIK3CA—ovarian cancer	8.09e-06	9.79e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PIK3CG—ovarian cancer	8.03e-06	9.72e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TP53—ovarian cancer	7.82e-06	9.47e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—AKT1—ovarian cancer	7.61e-06	9.21e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—HRAS—ovarian cancer	7.48e-06	9.06e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IL6—ovarian cancer	7.16e-06	8.67e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PIK3CD—ovarian cancer	7.05e-06	8.54e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—AKT1—ovarian cancer	6.61e-06	8e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PIK3CA—ovarian cancer	6.23e-06	7.55e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PIK3CB—ovarian cancer	6.15e-06	7.45e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PIK3CA—ovarian cancer	5.73e-06	6.94e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PTEN—ovarian cancer	5.31e-06	6.43e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—AKT1—ovarian cancer	5.09e-06	6.17e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—AKT1—ovarian cancer	4.68e-06	5.67e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PIK3CA—ovarian cancer	3.75e-06	4.54e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—AKT1—ovarian cancer	3.06e-06	3.71e-05	CbGpPWpGaD
